30 Years of Evidence

Take a moment to explore a selection of publications and conference abstracts from around the globe. Find evidence for a wide range of treatment sites including malignant and benign disease, different fractionation schedules and real-time motion synchronization techniques for the CyberKnife® and Radixact®/ TomoTherapy® platforms. We update new papers on a regular basis. See how health professionals are helping to improve patient outcomes.

CyberKnife Stereotactic Ablative Radiotherapy for Recurrent or Oligometastatic Gynecological Cancers

Kataria T, Naga P, Banerjee S, Gupta D, Narang K, Tayal M, Bisht SS | South Asian J Cancer | 2021

Multicenter Trial of Stereotactic Body Radiation Therapy for Low- and Intermediate-Risk Prostate Cancer: Survival and Toxicity Endpoints

Meier RM, Bloch DA, Cotrutz C, Beckman AC, Henning GT, Woodhouse SA, Williamson SK, Mohideen N, Dombrowski JJ, Hong RL, Brachman DG, Linson PW, Kaplan ID. | Int J Radiat Oncol Biol Phys | 2018

Patient and Dosimetric Predictors of Genitourinary and Bowel Quality of Life After Prostate SBRT: Secondary Analysis of a Multi-institutional Trial

Wang K, Chen RC, Kane B, Medbery CA, Underhill K, Gray JR, Peddada AV, Fuller DB | Int J Radiat Oncol Biol Phys | 2018

5-year Biochemical Outcomes of Stereotactic Body Radiotherapy with Intraprostatic Dose Escalation for Unfavorable Prostate Cancer

Blacksburg SR, Aghdam N, Royce TJ, Burri RJ, Obayomi-Davies O, Mezeckis M, Meier R, Fuller DB, Chen RC, Lanciano RM, Haas JA, Collins SP | Int J Radiat Oncol Biol Phys | 2019

Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial

Brand DH, Tree AC, Ostler P, van der Voet H, Loblaw A, Chu W, Ford D, Tolan S, Jain S, Martin A, Staffurth J, Camilleri P, Kancherla K, Frew J, Chan A, Dayes IS, Henderson D, Brown S, Cruickshank C, Burnett S, Duffton A, Griffin C, Hinder V, Morrison K, Naismith O, Hall E, van As N; PACE Trial Investigators | Lancet Oncol | 2019

Prostate SBRT: Comparison the Efficacy and Toxicity of Two Different Dose Fractionation Schedules

Fuller DB, Naitoh J, Shirazi R, Crabtree T, Mardirossian G | Front Oncol | 2020

Favorable Biochemical Freedom From Recurrence With Stereotactic Body Radiation Therapy for Intermediate and High-Risk Prostate Cancer: A Single Institutional Experience With Long-Term Follow-Up

Ricco A, Barbera G, Lanciano R, Feng J, Hanlon A, Lozano A, Good M, Arrigo S, Lamond J, Yang J | Front Oncol | 2020

Acute side effects after definitive stereotactic body radiation therapy (SBRT) for patients with clinically localized or locally advanced prostate cancer: a single institution prospective study

Jorgo K, Polgar C, Stelczer G, Major T, Gesztesi L, Agoston P | Radiol Oncol | 2021

Bleeding Risk Following Stereotactic Body Radiation Therapy for Localized Prostate Cancer in Men on Baseline Anticoagulant or Antiplatelet Therapy

Pepin A, Shah S, Pernia M, Lei S, Ayoob M, Danner M, Yung T, Collins BT, Suy S, Aghdam N, Collins SP | Front Oncol | 2021

Five-year outcomes of stereotactic body radiation therapy (SBRT) for prostate cancer: the largest experience in China

Zhao X, Ye Y, Yu H, Jiang L, Cheng C, Guo X, Ju X, Zhu X, Zhang H. | J Cancer Res Clin Oncol | 2021

Bothersome Hematospermia Following Stereotactic Body Radiation Therapy for Prostate Cancer

Sarthak Shah, Tamir Sholklapper , Michael Creswell, Abigail Pepin , Jonathan Cantalino, Ryan Andrew Hankins, Simeng Suy, Sean P Collins | Front Oncol | 2021